Correction to: In vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1-34 loaded pegylated chitosan nanoparticles (Molecular Pharmaceutics (2013) 10: 11 (4159-4167) DOI: 10.1021/mp400184v);In vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1-34 loaded PEGylated chitosan nanoparticles

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 4159-4167

  Narayanan, Deepa ^a   Anitha, A ^a   Jayakumar, R ^a   Chennazhi, K P ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

improved half life; oral peptide delivery; osteoporosis; PEGylated chitosan nanoparticle; PTH 1 34

Indexed keywords

ALKALINE PHOSPHATASE; CHITOSAN; MACROGOL 200; NANOPARTICLE; OSTEOCALCIN; PARATHYROID HORMONE[1-34];

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CALCIUM CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; CROSS REACTION; DRUG BIOAVAILABILITY; FEMALE; GASTROINTESTINAL TRANSIT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; LIMIT OF DETECTION; NANOENCAPSULATION; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; STATIC ELECTRICITY; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; CALORIMETRY; CELL PROLIFERATION; CHITOSAN; FEMALE; NANOPARTICLES; OSTEOPOROSIS; PARATHYROID HORMONE; POLYETHYLENE GLYCOLS; RATS;

EID: 84887358368     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.9b00171     Document Type: Erratum

References (52)

1. Penrod, J.; Smith, A. M.; Terwilliger, S.; Gueldner, S. H. Prevalence, risk factors, and pathogenesis. In Osteoporosis: clinical guidelines for prevention, diagnosis, and management; Gueldner, S. H., Grabo, T. N., Newman, E. D., Cooper, D. R., Eds.; Springer Publishing: New York, 2007; pp 9-11.
2. Matthew, S.; Sharon, B.; Midura, R. J. M. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair Bone 2009, 45, 590-602
3. Jilka, R. L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH Bone 2007, 40, 1434-1446
4. Lotinun, S.; Sibonga, J. D.; Turner, R. T. Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression Endocrine 2002, 17, 29-36
5. Medication guide Forteo teriparatide rDNA origin injection, Eli Lilly. 2010. http://pi.lilly.com/us/forteo-pi.pdf.
6. Werle, M.; Samhaber, A.; Bernkop-Schnürch, A. Degradation of teriparatide by gastro-intestinal proteolytic enzymes J. Drug Targeting 2006, 14, 109-15
7. Leanes, M. M.; Nankervis, R.; Smith, A.; Illum, L. Use of the ninhydrin assay to measure the release of chitosan from oral solid dosage forms Int. J. Pharm. 2004, 271, 241-249
8. Senel, S.; Ikinci, G.; Kas, S.; Yousefi-Rad, A.; Hincal, A. A. Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery Int. J. Pharm. 2000, 193, 197-203
9. Senel, S.; Kremer, M. J.; Kas, S.; Wertz, P. W.; Hincal, A. A.; Squier, C. A. Enhancing effect of chitosan on peptide drug delivery across buccal mucosa Biomaterials 2000, 21, 2067-2071
10. Smith, J.; Wood, E.; Dornish, M. Effect of chitosan on epithelial cell tight junction Pharm. Res. 2004, 21, 43-49
11. Andreas, B. S. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems Int. J. Pharm. 2000, 194, 1-13
12. Jung, T.; Kamm, W.; Breitenbach, A.; Kaiserling, E.; Xiao, J. X.; Kissel, T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake Eur. J. Pharm. Biopharm. 2000, 50, 147-160
13. Alves, N. M.; Mano, J. F. Chitosan derivatives obtained by chemical modifications for biomedical and environmental applications Int. J. Biol. Macromol. 2008, 43, 401-414
14. Ehrlich, H. E. Biological materials of marine origin: Invertebrates; Monograph; Springer Verlag: Dordrecht, 2010; p 569.
15. Sonia, T. A.; Sharma, C. P. Chitosan and its derivatives for drug delivery perspective Adv. Polym. Sci. 2011, 243, 23-54
16. Muzzarelli, R. A. Biomedical exploitation of chitin and chitosan via mechano-chemical disassembly, electrospinning, dissolution in imidazolium ionic liquids, and supercritical drying Mar. Drugs 2011, 9, 1510-1533
17. Mao, S.; Shuai, X.; Unger, F.; Simon, M. The depolymerisation of chitosan: effects on physicochemical and biological properties Int. J. Pharm. 2004, 281, 45-54
18. Jayakumar, R.; Chennazhi, K. P.; Muzzarelli, R. A. A.; Tamura, H.; Nair, S. V.; Selvamurugan, N. Chitosan conjugated DNA nanoparticles in gene therapy Carbohydr. Polym. 2010, 7, 91-98
19. Jayakumar, R.; Menon, D.; Manzoor, K.; Nair, S. V.; Tamura, H. Biomedical applications of chitin and chitosan based nanomaterials-A short review Carbohydr. Polym. 2010, 82, 227-232
20. Anitha, A.; Divya Rani, V. V.; Krishna, R.; Sreeja, V.; Selvamurugan, N.; Nair, S. V. Synthesis, characterization, cytotoxicity and antibacterial studies of chitosan, O -carboxymethyl and N,O -carboxymethyl chitosan nanoparticles Carbohydr. Polym. 2009, 78, 672-677
21. Anitha, A.; Deepagan, V. G.; Divya Rani, V. V.; Menon, D.; Nair, S. V.; Jayakumar, R. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles Carbohydr. Polym. 2011, 84, 1158-1164
22. Muzzarelli, R. A. A. Chitosan composites with inorganic, morphogenetic proteins and stem cells, for bone regeneration Carbohydr. Polym. 2011, 83, 1433-1445
23. Douglas, K. L.; Piccirillo, C. A.; Tabrizian, M. Effects of alginate inclusion on the vector properties of chitosan-based nanoparticles J. Controlled Release 2006, 115, 354-361
24. Deepa, N.; Anitha, A.; Jayakumar, R.; Nair, S. V.; Chennazhi, K. P. Synthesis, characterization and preliminary in vitro evaluation of PTH 1-34 loaded chitosan nanoparticles for osteoporosis J. Biomed. Nanotechnol. 2012, 8, 98-106
25. Luca, C.; Driton, V.; Enzo, C.; Snjezana, S.; Steven, H.; Lisbeth, I. PEGylated chitosan derivatives: Synthesis, characterizations and pharmaceutical applications Prog. Polym. Sci. 2012, 37, 659-685
26. Zabaleta, V.; Ponchel, G.; Salman, H.; Agüeros, M.; Vauthier, C.; Irache, J. M. Oral administration of paclitaxel with pegylated polyanhydride nanoparticles: permeability and pharmacokinetic study Eur. J. Pharm. Biopharm. 2012, 81, 514-523
27. Prego, C.; Torres, D.; Fernandez-Megia, E.; Novoa-Carballal, R.; Quiñoá, E.; Alonso, M. J. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery-Effect of chitosan PEGylation degree J. Controlled Release 2006, 111, 299-308
28. Tobío, M.; Sánchez, A.; Vila, A.; Soriano, I.; Evora, C.; Vila-Jato, J. L.; Alonso, M. J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration Colloids Surf., B 2000, 18, 315-323
29. Kimura, T.; Sudo, K.; Kanzaki, Y.; Miki, K.; Takeichi, Y.; Kurosaki, Y.; Nakayama, T. Drug absorption from large intestine: physicochemical factors governing drug absorption Biol. Pharm. Bull. 1994, 17, 327-33
30. Anitha, A.; Chennazhi, K. P.; Nair, S. V.; Jayakumar, R. 5-Flourouracil loaded N, O -carboxymethyl chitosan nanoparticles as an anticancer nanomedicine for breast cancer J. Biomedical. Nanotechnol. 2012, 8, 1-14
31. McConnell, E. L.; Basit, A. W.; Murdan, S. Measurement of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in vivo experiments J. Pharm. Pharmacol. 2008, 1, 63-70
32. Sanoj, R. N.; Muthunarayanan, M.; Divyarani, V. V.; Sreerekha, P. R.; Chennazhi, K. P.; Nair, S. V.; Tamura, H.; Jayakumar, R. Curcumin-loaded biocompatible thermo-responsive polymeric nanoparticles for cancer drug delivery J. Colloid Interface Sci. 2011, 360, 39-51
33. Alice, F.; Maria, C. M.; Francesco, L.; Francesca, M.; Anna, M. M.; Chiara, S. Cavitation effect on chitosan nanoparticle size: A possible approach to protect drugs from ultrasonic stress Carbohydr. Polym. 2013, 94, 619-625
34. NIST Chemistry WebBook (http://webbook.nist.gov/chemistry).
35. Shi, S.; Jia, J.; Guo, X.; Zhao, Y.; Chen, D.; Guo, Y.; Cheng, T.; Zhang, X. Biocompatibility of chitosan-coated iron oxide nanoparticles with osteoblast cells Int. J. Nanomed. 2012, 7, 5593-5602
36. Powell, D. W. Barrier function of epithelia Am. J. Physiol. 1981, 24, 1275-1288
37. Pappenheimer, J. R.; Reiss, K. Z. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat J. Membr. Biol. 1987, 100, 123-136
38. Pauletti, G. M.; Okumu, F. W.; Borchardt, R. T. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway Pharm. Res. 1997, 14, 164-168
39. Taylor, D. C.; Leahy, D. E. In Drug delivery to the gastrointestinal tract; Hardy, J. G.; Wilson, C. C., Eds.; Ellis Horwood: Chichester, U.K., 1989; pp 133-145.
40. Mahato, R. I.; Narang, A. S.; Thoma, L.; Miller, D. D. Emerging trends in oral delivery of peptide and protein drugs Crit. Rev. Ther. Drug Carrier Syst. 2003, 20, 153-214
41. Brader, M. L.; Sukumar, M.; Pekar, A. H.; McClellan, D. S.; Chance, R. E.; Flora, D. B. Hybrid insulin cocrystals for controlled release delivery Nat. Biotechnol. 2002, 20, 800-804
42. Fang, N.; Chan, V.; Mao, H. Q. Interactions of phospholipids bilayer with chitosan: effect of molecular weight and pH Biomacromolecules 2001, 2, 1161-1168
43. Thanou, M.; Verhoef, J. C.; Junginger, H. E. Chitosan and its derivatives as intestinal absorption enhancers Adv. Drug Delivery Rev. 2001, 50, 91-101
44. Artursson, P.; Lindmark, T.; Davis, S. S. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells Caco-2 Pharm. Res. 1994, 11, 1358-1361
45. Dodane, V.; Khan, M. A.; Merwin, J. R. Effect of chitosan on epithelial permeability and structure Int. J. Pharm. 1999, 182, 21-32
46. Driton, V.; Ruth, E.; Angeles, H.; Luca, C.; Martin, G.; Lisbeth, I.; Snow, S. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution Int. J. Pharm. 2010, 400, 183-193
47. Hsiao, S. W.; Thien, D. V.; Ho, M. H.; Hsieh, H. J.; Li, C. H.; Hung, C. H.; Li, H. H. Interactions between chitosan and cells measured by AFM Biomed. Mater. 2010, 5, 054117
48. Julie, S.; Michael, H.; Paul, D. M.; Fernando, M.; Emmett, V. G.; Harald, D. Pharmacokinetics of teriparatide and calcium pharmacodynamics in postmenopausal women with osteoporosis Calcif. Tissue Int. 2010, 87, 485-492
49. Andrea, L.; Masahiko, S.; Duncan, P.; Ann, H. H.; Donald, S.; Monica, C.; James, C.; James, M.; Robert, A. B. Oral delivery of biologically active Parathyroid hormone Pharm. Res. 2001, 18, 964-970
50. 2 in postmenopausal women with osteoporosis Bone 2013, 53, 160-166
51. Zhao, S. H.; Wu, X. T.; Guo, W. C.; Du, Y. M.; Yu, L.; Tang, J. N-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride nanoparticle as a novel delivery system for parathyroid hormone-related protein 1-34 Int. J. Pharm. 2010, 393, 268-272
52. Zhou, H.; Shen, V.; Dempster, D. W.; Lindsay, R. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat J. Bone Miner. Res. 2001, 16, 1300-1307